Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease

  • End date
    Jul 4, 2023
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 27 October 2022


This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study.

The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin.

In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine.

In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine.

Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call.

Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

Condition Kidney Disease, Chronic
Treatment Empagliflozin, BI 690517, Placebo to Empagliflozin, Placebo to BI 690517
Clinical Study IdentifierNCT05182840
SponsorBoehringer Ingelheim
Last Modified on27 October 2022


Yes No Not Sure

Inclusion Criteria

Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Male or female patients of legal adult age (according to local legislation) and aged ≥ 18 years at time of consent
estimated Glomerular Filtration Rate (eGFR, Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 30 and < 90 mL/min/1.73 m2 at Visit 1 by central laboratory analysis
Urine Albumin Creatinine Ratio (UACR) ≥ 200 and < 5,000 mg/g in spot urine (midstream urine sample) by central laboratory analysis at Visit 1.1
If the patient is taking any of the following medications they should be on a stable dose for at least 4 weeks prior to visit 1 and until first randomisation prior to run-in with no planned change of the therapy during the trial: anti-hypertensives, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), endothelin receptor antagonists, low dose systemic steroids (e.g. prednisolone ≤10 mg or equivalent)
Treatment with a clinically appropriate, stable dose of either Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) (but not both together), for ≥ 4 weeks prior to visit 1 and until first randomisation with no planned change of the therapy during the trial
In the Investigator's opinion, any kind of diagnosed chronic kidney disease (Diagnosis can be reached by standard clinical method, no biopsy required). Patients with diabetic kidney disease must have type 2 diabetes mellitus and their treatment (including GLP1 receptor agonist) should be unchanged or changes deemed minor (according to investigator's judgement) within 4 weeks prior to Visit 1 and until first randomisation
Glycated Haemoglobin (HbA1c) < 10.0% at Visit 1 measured by the central laboratory
Serum potassium ≤ 4.8 mmol/L at Visit 1 measured by the central laboratory
Seated Systolic Blood Pressure (SBP) ≥ 110 and ≤ 160 mmHg and Diastolic Blood Pressure (DBP) ≥ 65 and ≤ 110 mmHg at Visit 1 (mean values from three Blood Pressure (BP) measurements) and optimised anti-hypertensive treatment according to local standard of care and investigator's judgement
Body Mass Index (BMI) ≥ 18.5 and < 50 kg/m2 at Visit 1
Women of child-bearing potential2 (WOCBP) must be ready and able to use highly effective methods of birth control. Such methods should be used throughout the trial. Men must be vasectomised or willing and able to use a condom if their partner is a WOCBP
Additional inclusion criteria to be assessed before second randomisation (start of
Treatment Period)
Serum potassium ≤ 4.8 mmol/L measured by local or central laboratory within 7 days
prior to randomisation to the Treatment Period
eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20
mL/min/1.73 m2 measured by local or central laboratory within 7 days prior to
randomisation to the Treatment Period

Exclusion Criteria

Treatment with inhibitors of aldosterone mediated effects (e.g., mineralocorticoid
receptor antagonists such as spironolactone), or intake of other potassium sparing
diuretics (e.g., amiloride) within 7 days prior to first randomisation or planned
during trial treatment phase
Treatment with other Renin Angiotensin Aldosterone System (RAAS) interventions (apart
from either Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor
Blocker (ARB)) within 4 weeks prior to Visit 1 and throughout screening or planned
during the trial. Patients who must or wish to continue the intake of restricted
medications or any drug considered likely to interfere with the safe conduct of the
trial are also excluded
Type 1 diabetes mellitus, or history of other autoimmune causes of diabetes mellitus
(e.g. Latent Autoimmune Diabetes (LADA))
Patients at increased risk of ketoacidosis in the opinion of the investigator
Currently receiving Sodium-glucose cotransporter (SGLT)-2 or SGLT-1/2 inhibitor or
planned initiation during the trial
Further criteria apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note